Incyte Corporation — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Unaudited consolidated results. Incyte is a biopharmaceutical company with commercial products and a clinical-stage development pipeline.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $911.4m | $705.7m | $1,644.6m | $1,310.4m |
| Operating income | $254.4m | $140.8m | $371.0m | $239.6m |
| Net income | $161.4m | $149.5m | $199.4m | $203.0m |
| Diluted EPS | $0.72 | $0.67 | $0.89 | $0.91 |
| Operating margin | 27.9% | 20.0% | 22.6% | 18.3% |
- Q2 revenue increased 29% year over year; six-month revenue rose 25%. Product revenue was $663.9m in Q2, including $597.7m from JAKAFI. Royalties were $117.5m, while milestone and contract revenue was $130.0m.
- Q2 operating income increased 81%, but net income rose only 8%, partly reflecting a $24.9m unrealized loss on long-term investments versus a $26.8m gain in Q2 2021. For the six months, investment losses were $71.5m versus $0.9m in the prior-year period.
- Q2 R&D expense was $347.2m, up modestly year over year; SG&A was $253.3m, up from $168.9m, mainly reflecting dermatology commercialization and OPZELURA launch activities. Six-month R&D was $700.6m and SG&A was $462.9m.
- Operating cash flow for the six months was $389.9m, compared with $379.0m. Investing cash use was $29.2m and financing cash provided was $16.0m. Cash, cash equivalents and marketable securities totaled approximately $2.7bn at June 30.
- Total assets were $5.32bn and total liabilities $1.23bn at June 30. The company had no borrowings under its $500m revolving credit facility; finance lease liabilities totaled $34.2m. Current assets were $3.63bn versus current liabilities of $926.7m.
Material changes and notable items
- JAKAFI revenue grew to $597.7m in Q2 from $529.1m, driven by higher volume and price. It remains the company’s principal product revenue source.
- Newer product revenues included OPZELURA ($16.6m) and MINJUVI ($4.4m) in Q2; neither had comparable Q2 2021 revenue. Product royalty revenue declined slightly in Q2, including lower OLUMIANT royalties, while six-month royalties increased.
- Milestone revenue included $60m under the Novartis agreement and $70m under the Lilly agreement in the first half, plus $5m from Innovent. These milestones materially contributed to revenue growth.
- Six-month net income declined despite higher revenue and operating income. Income tax expense rose to $100.5m from $38.0m; the filing attributes the comparison partly to the 2021 release of a majority of the U.S. valuation allowance, which generated a $569m tax benefit in Q4 2021.
- Long-term investments fell to $149.8m from $221.3m at year-end 2021, with mark-to-market losses contributing to earnings volatility. Inventory increased to $94.1m from $56.9m.
Outlook, risks and contingencies
- Management said operating cash flow, existing cash and securities, and facility availability should meet capital needs for the foreseeable future. No specific revenue or earnings guidance was provided in the filing.
- Management noted that U.S. cash tax payments are expected to increase because tax rules now require capitalization and amortization of R&D costs.
- Key risks include reliance on JAKAFI, concentration in a limited number of specialty pharmacies, wholesalers and customers, pricing and reimbursement pressure, competition and patent challenges, clinical and regulatory uncertainty, and reliance on external manufacturers and collaborators.
- Development setbacks include withdrawal of the parsaclisib U.S. NDA after discussions with the FDA and withdrawal of its EU application for marginal zone lymphoma in July 2022. Retifanlimab received an FDA complete response letter for anal cancer. The company also discontinued development of itacitinib in treatment-naive chronic GVHD and opted out of Merus’s MCLA-145 program.
- Product safety labeling, including class warnings concerning certain risks associated with JAK inhibitors, may affect JAKAFI and OPZELURA. The filing also describes potential disruption from COVID-19, geopolitical events, clinical-trial delays, and supply constraints.
- Contingent acquisition consideration was $237m at June 30, including $36.9m current. The filing discusses ordinary-course legal matters but does not provide a clear quantified loss exposure.
- After quarter-end, OPZELURA was approved for nonsegmental vitiligo in July 2022; Incyte also disclosed a July MacroGenics amendment and $30m payment.
Important facts for investors to verify
- How much future revenue and earnings depend on JAKAFI, and the pace of growth of OPZELURA and other newer products.
- The sustainability of milestone and royalty revenue and the effect of collaborator decisions on future receipts.
- Whether SG&A and R&D spending, particularly dermatology commercialization and late-stage development costs, translate into durable growth.
- The drivers and potential persistence of investment-related earnings volatility and higher cash taxes.
- Updates on parsaclisib, retifanlimab, other clinical programs, product reimbursement, manufacturing capacity, and JAKAFI patent challenges.